1. Home
  2. STVN vs JHG Comparison

STVN vs JHG Comparison

Compare STVN & JHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STVN
  • JHG
  • Stock Information
  • Founded
  • STVN 1949
  • JHG 1934
  • Country
  • STVN Italy
  • JHG United Kingdom
  • Employees
  • STVN N/A
  • JHG N/A
  • Industry
  • STVN Containers/Packaging
  • JHG Investment Managers
  • Sector
  • STVN Consumer Discretionary
  • JHG Finance
  • Exchange
  • STVN Nasdaq
  • JHG Nasdaq
  • Market Cap
  • STVN 5.7B
  • JHG 5.8B
  • IPO Year
  • STVN 2021
  • JHG N/A
  • Fundamental
  • Price
  • STVN $19.27
  • JHG $30.06
  • Analyst Decision
  • STVN Buy
  • JHG Buy
  • Analyst Count
  • STVN 7
  • JHG 12
  • Target Price
  • STVN $26.93
  • JHG $43.50
  • AVG Volume (30 Days)
  • STVN 365.9K
  • JHG 1.5M
  • Earning Date
  • STVN 03-06-2025
  • JHG 05-01-2025
  • Dividend Yield
  • STVN 0.29%
  • JHG 4.76%
  • EPS Growth
  • STVN N/A
  • JHG 8.02
  • EPS
  • STVN 0.45
  • JHG 2.56
  • Revenue
  • STVN $1,143,012,735.00
  • JHG $2,473,200,000.00
  • Revenue This Year
  • STVN $8.60
  • JHG $6.18
  • Revenue Next Year
  • STVN $12.43
  • JHG $9.03
  • P/E Ratio
  • STVN $45.67
  • JHG $12.80
  • Revenue Growth
  • STVN 1.72
  • JHG 17.67
  • 52 Week Low
  • STVN $16.56
  • JHG $30.35
  • 52 Week High
  • STVN $31.41
  • JHG $46.68
  • Technical
  • Relative Strength Index (RSI)
  • STVN 41.47
  • JHG 21.74
  • Support Level
  • STVN $20.11
  • JHG $35.10
  • Resistance Level
  • STVN $21.21
  • JHG $36.95
  • Average True Range (ATR)
  • STVN 1.02
  • JHG 0.96
  • MACD
  • STVN -0.15
  • JHG -0.40
  • Stochastic Oscillator
  • STVN 8.51
  • JHG 1.54

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

About JHG Janus Henderson Group plc

Janus Henderson Group provides investment management services to retail intermediary (56% of managed assets), self-directed (23%) and institutional (21%) clients. At the end of September 2024, active equities (63%), fixed-income (21%), multi-asset (14%) and alternative (2%) investment platforms constituted the company's $382.3 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (61%), with customers from Europe, the Middle East, Africa, and Latin America (29%) and the Asia-Pacific region (10%) accounting for the remainder.

Share on Social Networks: